Kornimate/medical-research-clean huggingface dataset:
korean cardiac arrest research consortium

Conditions: Out-of-Hospital Cardiac Arrest

Summary: this study will evaluated the epidemiology and the outcomes of patients suffering out-of-hospital cardiac arrest with presumed cardiac etiology in korea.

the korean cardiac arrest research consortium (kocarc) is a collaborative research network developed to comprehend various researches conducted in the field of out-of-cardiac arrest resuscitation and to strengthen the cooperative effort in conducting studies. it was organized in 2014 with recruitment of hospitals willing to participate voluntarily to the consortium. not only for emergency medicine, but kocarc is expanding the research collaboration with cardiology, preventive medicine and epidemiology as well. to enhance the professionalism and effectiveness in research, seven research committees, which consists of epidemiology and preventive research committee (epr), community resuscitation research committee (crr), ems resuscitation research committee (err), hospital resuscitation research committee (hrr), hypothermia and post-resuscitation care research committee (hpr), cardiac care resuscitation committee (ccr) and pediatric resuscitation research committee (prr). also data safety and monitoring board committee (dsmb) is organized to provide annual review and security and ethics committee to oversight security and ethical issues in research. monthly meeting of interdisciplinary steering committee, consists of the consortium chair, steering committee chair, each research committee chair and secretary committee, is held to approve the proposed research agendas and to mediate between multi-center trial participating hospitals. kocarc registry is a data collecting system composed of ohca risk and prognostic variables developed to provide the platform to researches conducted in kocarc.

Eligibility criteria:
inclusion criteria: * ohca patients who were transported to participating emergency department (ed) by emergency medical service with resuscitation efforts and whose arrest was identified as a presumed cardiac etiology by emergency physicians in ed. exclusion criteria: * ohca with terminal illness documented by medical record, under hospice care, with pregnancy, with pre-documented 'do not resuscitate' card * ohca of definite non-cardiac etiology, including trauma, drowning, poisoning, burn, asphyxia, or hanging

Keywords: out-of-hospital cardiac arrest
intradermal versus intramuscular trivalent influenza vaccine in adult solid organ transplant recipients

Conditions: Influenza Vaccine

Summary: influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia and contribute to the development of rejection. although the annual influenza vaccine is recommended for transplant patients, studies have shown that a single intramuscular dose has poor immunogenicity. there are no studies that define the effect of intradermal doses in this population. we plan to study the immunogenicity of two different administration routes of the influenza vaccine in 200 solid organ transplant patients during the 2010-2011 season. patients will be randomized to receive influenza vaccine either intradermally or intramuscularly. we hypothesize that the patients who receive the intradermal influenza vaccine will significantly reach a higher response to the vaccine. this study advances research on the prevention of serious viral infections in transplant recipients. results from this study have the potential to directly improve patient care. if the use of the intradermal influenza vaccine is successful, this strategy may lead to a significant reduction in burden of disease, hospitalizations, and long-term morbidity.


Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 59, * greater than 3 months post-transplant, * any solid organ transplant (kidney, liver, heart, lung, pancreas, intestinal or combinations of the aforementioned organs) exclusion criteria: * has already received influenza vaccination for 2010-2011 season; * egg allergy, * previous life-threatening reaction to influenza vaccine (i.e. guillain barre syndrome), * ongoing therapy for rejection, * febrile illness in the past two weeks, * unable to provide informed consent, * unable to comply with study protocol

Keywords: adult solid organ transplant patients
us guided wallant vs cpb block for clavicle surgery

Conditions: Clavicle Fracture; Clavicle Injury

Summary: the clavicle is frequently fractured bone. regional anesthesia (ra) for clavicle surgery is always challenging due t complex innervation from the two plexuses (cervical and brachial). various ra techniques described for clavicle surgery include plexus blocks, fascial plane blocks,and truncal blocks.

clavipectoral fascial plane block (cpb) is most commonly used as an anesthesia and postoperative analgesia technique to clavicle surgery. this study is deigned to evaluate the feasibility of wide awake local anesthesia no tourniquet (walant) technique as a sole anesthesia in clavicle surgery, clavipectoral (cvp) fascia plane block + superficial cervical plexus plane block (cpb) as a sole anesthesia technique in clavicle surgery by using intraoperative verbal rating score (vrs) to determine how many patients need analgesia, sedation or convert to general anesthesia (ga), and postoperative assessment of patient satisfaction and 24 hour postoperative opioid consumption.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) 1,2 * unilateral clavicle fracture. exclusion criteria: * psychologically unstable patient. * uncooperative patient. * patient refusal to be awake during surgery. * allergy. * infection at site of infection.

Keywords: wide awake local anesthesia clavipectoral fascia plane block clavicle surgery
the peer genetic study

Conditions: Healthy Subject; Prostate Carcinoma

Summary: this trial studies how well a peer-based health education program works in reducing barriers and changing attitudes and beliefs of prostate cancer genetic screening in african american participants with or without a previous personal or family history of prostate cancer. participating in a peer-based health educational program may help participants learn more about prostate cancer and how their personal or family history of disease may increase their risk of prostate cancer.


Eligibility criteria:
inclusion criteria: * able to read and speak english comfortably * with or without a personal or family history of pca * do not need to be an established patient at citylife neighborhood clinic in order to participate exclusion criteria: * do not read or speak english comfortably * men who participated in a focus group will be excluded from participating in the intervention
tumor microenvironment surveillance on simultaneous liver metastases extensive stage small cell lung cancer

Conditions: Extensive Stage Small Cell Lung Cancer

Summary: the purpose of the trial is to detect tumor microenvironment on extensive stage small cell lung cancer with simultaneous liver metastases who treated with atezolizumab plus etoposide and platinum based chemotherapy.


Eligibility criteria:
inclusion criteria: * 18， extensive stage small cell lung cancer confirmed by histopathology treated with atezolizumab plus etoposide and platinum based chemotherapy exclusion criteria: - patients with contraindication of chemotherapy pregnant or breast feeding women
porous metronidazole loaded matrix for local treatment of periodontitis.

Conditions: Chronic Periodontitis

Summary: aim of the study is the efficiency assessment of porous metronidazole loaded matrix based on gelatin/hydroxyethylcellulose blend in treatment of deep periodontal pockets resulting from severe chronic periodontitis. the matrix was invented and produced in department of drug form technology, wroclaw medical university. the porous metronidazole (mtz) loaded matrix was fabricated by the freeze-drying technique. the morphology, mechanical properties, in vitro degradation, mtz release from dried sponge were evaluated and also the clinical trials were performed. patients suffering from chronic periodontitis are examined. to evaluate oral hygiene api (approximal plaque index) and the gum inflammation bop (bleeding on probing) and pbi (papilla bleeding index) indices are used. the clinical examination is performed 3 times. on the first visit the output indicators are defined. the subgingival scaling is performed and metronidazol on porous matrix is applied to the selected periodontal pockets. 2 control tests of periodontal indices are carried out after one week and one month from the application. in the control group after scaling/root planing procedure, there is no application of metronidazole.


Eligibility criteria:
inclusion criteria: * non-smokers * suffering from chronic periodontitis exclusion criteria: * any antibiotics taken systematically or locally in the preceding six months

Keywords: periodontitis treatment periodonal pockets local delivery drugs
effects of nonpharmacological interventions in sleep quality, anxiety, and delirium for patients of adult intensive care units

Conditions: Intensive Care Unit; Critical Care; Sleep Quality; Anxiety; Delirium

Summary: this study will investigate the effect of nonpharmacological intervention in sleep quality, anxiety and delirium among adult icu patients.

background: due to the intensive care unit (icu) noisy environment, nearly 66% critically ill patientsseem to suffer from poor sleep quality, which can easily lead to complications, such as anxiety, delirium, prolong hospital stay, and even increased mortality. objective: this study will investigate the effect of nonpharmacological intervention in sleep quality, anxiety and delirium among adult icu patients. methods: the design of this study is a randomized experimental study recruiting 154 patients from five adult icus in a teaching hospital located in the central southern taiwan. the experimental group (n=77, nonpharmacological intervention, and the control group (n=77, routine care). the nonpharmacological intervention involves listening of 30 mins ocean wave music, aromatherapy of lavender essential oil, and eye masks and earplugs. research measurement tools, including demographic data, physiological index questionnaire, richards-campbell sleep scale (rcsq), chinese visin-style sleep scale, chinese state -trait anxiety inventory-1, visual analogue scale for anxiety, which will be measured five times, before intervention (t1), every 9am for three days (t2, t3, t4), and icu transferring day (t5). spss 26.0 will be used to analyze data by using descriptive statistics, chi-square test, pearson correlation, independent t-test, paired t-test, anova, generalized estimating equation (gee).

Eligibility criteria:
inclusion criteria: * conscious and able to speak or write (gcs ≥ 11) * hemodynamically stable * normal hearing and able to communicate in a low voice * stay in icu for more than 24 hours * aged over 18 years. exclusion criteria: * pre-existing insomnia diagnosis with long-term reliance on sleep medication, * sleep-related medical history such as sleep apnea * shift work prior to hospitalization * diagnosis of alcohol abuse or schizophrenia * end-of-life or terminal conditions * allergy to essential oils * exclusion of dementia
sexual health impact of using pre-exposure hiv prophylaxis

Conditions: Pre-exposure HIV Prophylaxis (PrEP)

Summary: epidemiological and psychosociological survey of people on pre-exposure hiv prophylaxis (prep).

this study is perform to study the sexual health satisfaction of men who have sex with men (msm), since the use pre-exposure hiv prophylaxis (prep), compared to the time before prep.

Eligibility criteria:
inclusion criteria: * adult patient, male having sex with men, not infected with hiv, and using hiv prophylaxis by pre-exposure treatment (prep) for at least 1 year, received in consultation for renewal of this prescription. * able to give his non-opposition to participate in the research. * affiliation to a social security scheme. exclusion criteria: * patient under curatorship/guardianship or safeguard of justice * refusal to participate

Keywords: prep msm
evaluating the feasibility, acceptability and pre testing the impact of a self-management and tele monitoring program for copd patients in lebanon

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) has a significant impact on quality of life and is costly to the health care system. it has been demonstrated that a self-management program improves quality of life, but programs are not universally available and telehealth interventions can provide home-based support, but have mixed results. the aims of this study are to (1) assess the feasibility and acceptability of a 6 weeks' educational program related to self-management with remote monitoring for lebanese copd patients; (2) pre-test its impact on quality of life, emergency visits, and rate of rehospitalization, and (3) to make recommendations for a future randomized trial.

this study aims to evaluate the feasibility, acceptability and pre-test the impact of a nursing consultation and tele-monitoring in lebanon. it will be conducted at the hôtel-dieu de france (hdf) hospital, one of the largest university hospitals in beirut, and will use quantitative and qualitative methods in pre- and post-intervention to collect data over a period of 3 months. data will be collected by two researchers. a consent form will be signed by each participant prior to the intervention. patients will be informed about the purpose of the study, the course of the intervention, and the freedom to withdraw from the study at any time. their consent for the video recording will also be taken. this study is the first to evaluate the application of telehealth to optimize copd management in lebanon. the results of this study will provide evidence regarding the efficacy and feasibility of this approach for lebanese patients with moderate to severe copd.

Eligibility criteria:
inclusion criteria: * adult,18 years of age or older * male or female * outpatient * with moderate (gold 2) or severe (gold 3) copd. * cognitively capable, with an adequate health status to participate in the study according to the clinical consensus between nurses and physicians. exclusion criteria: * patients diagnosed with lung cancer * patients who have cognitive problems related to memory loss or speech disorders that would not allow a constructive exchange
study of chimeric monoclonal antibodies to shiga toxins 1 and 2

Conditions: Shiga Toxin Producing Bacterial Infection

Summary: this study is designed to evaluate the safety and efficacy of cαstx1 and cαstx2 administered concomitantly in children presenting early signs of shiga toxin-producing bacterial (stpb) infection.

currently, there is no etiological treatment of stpb-induced hus. ideally, such treatment would be started in the early phase of the infection and would protect against both types of toxins and all of their variants. the chimeric anti-shiga toxins 1 (cαstx1) and 2 (cαstx2) antibodies are intended to be administered as a single infusion and provide simultaneous protection against the two shiga toxins (stx1 and stx2) by decreasing the incidence and severity of shiga toxin-mediated clinical events including bloody diarrhea/hemorrhagic colitis and hemolytic uremic syndrome (hus) and associated sequelae.

Eligibility criteria:
inclusion criteria: 1. bloody diarrhea (by visual inspection) for no more than 36 hours prior to screening (signature of the informed consent). 2. detection of shiga toxin (stx1 and/or stx2) in stool exclusion criteria: 1. laboratory findings compatible with development of at least two out of three following criteria that define hemolytic uremic syndrome (hus): hemolytic anemia: hematocrit \ upper limit normal (uln) adjusted for age and gender. 2. bloody-diarrhea suspected not to be caused by shiga toxin-producing bacteria (stpb) but by other organisms or preexisting diseases. 3. family history of proven or suspected hereditary hemolytic uremic syndrome (hus) or thrombotic thrombocytopenic purpura (ttp). 4. history of chronic/recurrent hemolytic anemia or thrombocytopenia.

Keywords: shigamabs monoclonal antibodies shiga toxin e.coli hus bloody diarrhea
different doses of rosuvastatin therapy on regression of critical coronary atherosclerosis in acs patients

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to determine whether rosuvastatin 10mg/d or 20mg/d for 36 weeks can regress critical coronary atherosclerosis as determined by ivus imaging in chinese acute coronary syndrome (acs) patients.

this is a prospective, open-label, parallel group study to evaluate the efficacy of rosuvastatin 10mg/d or 20mg/d on critical coronary atherosclerosis in chinese acs patients. the anticipated duration of the study is approximately 36 weeks, patients with angiographic luminal diameter narrowing in any non-culprit site between 40%-70% will be enrolled from the study site. the primary efficacy parameter is the percent change of total atheroma volume (tav) of critical coronary atherosclerosis after 36 weeks of treatment. for inclusion in the study subjects should fulfill the following criteria: 1. provision of informed consent prior to any study specific procedures 2. 18 to 75 years old acs patients, male or female 3. the angiographic luminal diameter narrowing in any non-culprit site is between 40%-70% 4. statin-naive, defined as receiving no statin therapy within 3 monthsthe primary efficacy variable of the study is percent change of tav from baseline after rosuvastatin 10mg/d or 20mg/d for 36 weeks as determined by ivus imaging. the secondary efficacy variables are: * change of blood lipid level from baseline at 12th, 24th, 36nd week * change of inflammatory markers from baseline at 36nd week * change of percent atheroma volume (pav) as determined by ivus imaging at 36nd week

Eligibility criteria:
inclusion criteria: 1.provision of informed consent prior to any study specific procedures; 2.18 to 75 years old acs patients, male or female; 3.the angiographic luminal diameter narrowing in any non-culprit site is between 40%-70%; 4.statin-naive, defined as receiving no statin therapy within 3 months; exclusion criteria: 1. have received statin therapy within 3 months; 2. the angiographic luminal diameter narrowing in any coronary vessels is more than 70%; 3. active liver disease, alt≥3\*uln; 4. renal function damage, crcl\<30ml/min; 5. myopathy; 6. pregnancy, lactation female; 7. using cyclosporine; 8. patients with uncontrolled triglyceride levels tg≥5.65 mmol／l; 9. poorly controlled diabetes (hba1c≥10%）hypersensitivity to rosuvastatin or any of the recipients.

Keywords: ivus acs
comparison of pulse oximetry (spo2) with different oximeters and arterial saturation (sao2): oxygap2 study

Conditions: Respiratory Failure; Hypoxemia; Hyperoxemia

Summary: the oximeter is used to monitor intensive care patients undergoing oxygen therapy. it indicates pulsed oxygen saturation (spo2), a reflection of arterial oxygen saturation (sao2) which enables detection of hypoxemia and hyperoxia, both deleterious state. current spo2 recommendations aim to reduce both risk of hypoxemia and hyperoxia. spo2 is considered the 5th vital sign. current recommendations for spo2 targets do not consider the variability of oximeters used in clinical practice. this variability and lack of specification represent an obstacle to an optimal practice of oxygen therapy. thus, this study aims to compare the spo2 values of different oximeters (general electric-ge, medtronic, masimo and nonin) used in clinical practice with the sao2 reference value obtained by an arterial gas in order to specify the precision and the systematic biases of the oximeters studied. this data will also make it possible to refine the recommendations concerning optimal oxygenation


Eligibility criteria:
adult population inclusion criteria: * ≥ 18 years old (adult population) - * patients admitted to the intensive care unit * artery catheter already installed pediatric population * below 18 years old * patients admitted to the intensive care unit * artery catheter already installed exclusion criteria: * no or poor signal with the usual pulse oximeter/based on clinician judgment * high dose of vasopressors or inotropes (epinephrine or norepinephrine ˃ 1mcg/kg/min), shock state (lactates above 3 mmoles/l) * pigmented nails or nail polish * methemoglobinemia history * hemoglobin below 80 g/l * patient in isolation (multi-resistant bacteria, c-difficile, sars-cov-2...) * prone position, extra corporel membrane oxygenator
rituximab in patients with acute st-elevation myocardial infarction study

Conditions: Ischemic Heart Disease; Myocardial Infarction; Inflammation

Summary: rita-mi aims to develop of a novel therapeutic concept to target the immune response in patients with acute myocardial infarction (mi) by depleting b-cells with a single injection of rituximab which is approved for clinical use in cancer, autoimmune disease and inflammatory conditions. the goal is to re-purpose the drug, and translate the discovery into benefit for patients at high risk of cardiovascular events. rituximab is expected to limit infarction size and improve the healing process, as complementary to other therapeutic strategies. the applicants intend to perform a clinical study in patients with acute myocardial infarction (mi). the objective is to find the optimal dose (lowest dose with highest biological efficacy and best safety profile) for peripheral blood b cell depletion during the first 6 days after injection, and selective molecular signatures associated with improved heart function through analysis of peripheral blood samples. the study rationale is to decrease the inflammatory reaction upon tissue necrosis following heart muscle ischemia.


Eligibility criteria:
inclusion criteria: * age 18-75 years old * acute anterior (left anterior descending artery) stemi and successful primary percutaneous coronary intervention (pci) with stent implantation in the culprit lesion during the first 24h after onset of symptoms exclusion criteria: * a previous history of stemi * cardiogenic shock (systolic blood pressure \<80 mm hg, unresponsive to fluids, or necessitating catecholamines), electrical instability or severe congestive heart failure * residual severe proximal bystander disease awaiting inpatient revascularisation * corrected qt interval (qtc) \> 500 msecs using bazett's formula * hematologic abnormalities (hemoglobin \<10 g/dl or hematocrit \<30%, platelet cell count of \<100 x103/μl, white blood cell count \<4 x103/μl) * hypogammaglobulinaemia (defined as \<3g/l of igg) * renal failure (estimated gfr by the mdrd formula \< 45 ml/min/1.73m2); * known hepatic failure or abnormal liver function tests at baseline (alt \> 2 x uln). * active or recurrent hepatitis (type b). * known hiv infection * current or previous tuberculosis (chest x-ray) * current infections * presence or history in the previous five years of an ongoing cancer, except in situ cancer of the cervix or basal cell carcinoma * any oral or intravenous immunosuppressive treatment (other than concomitant 100 mg methylprednisolone), disease modifying drugs, or other immune modulatory monoclonal antibodies or immunodepleting therapy at any time * allergy to rituximab or one of its excipients * expected need for vaccination with a live attenuated vaccine during the study including incomplete vaccination courses. * known or suspected pregnancy at screening or lactating woman * women of childbearing age unless confirmed by direct questioning that they are reproductively sterile or post-menopausal * participation in other clinical trials * inability to comply with study procedures

Keywords: rituximab b cells